Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
8 "Liver cirrhosis"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Original Article
Diabetes, obesity and metabolism
Irisin Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis in Bile Duct Ligation Mice Model and Improves Mitochondrial Dysfunction
Thuy Linh Lai, So Young Park, Giang Nguyen, Phuc Thi Minh Pham, Seon Mee Kang, Jeana Hong, Jae-Ho Lee, Seung-Soon Im, Dae-Hee Choi, Eun-Hee Cho
Endocrinol Metab. 2024;39(6):908-920.   Published online November 5, 2024
DOI: https://doi.org/10.3803/EnM.2024.1984
  • 1,300 View
  • 96 Download
AbstractAbstract PDFPubReader   ePub   
Background
Liver fibrosis is a common outcome of chronic liver disease and is primarily driven by hepatic stellate cell (HSC) activation. Irisin, a myokine released during physical exercise, is beneficial for metabolic disorders and mitochondrial dysfunction. This study aimed to explore the effects of irisin on liver fibrosis in HSCs, a bile duct ligation (BDL) mouse model, and the associated mitochondrial dysfunction.
Methods
In vitro experiments utilized LX-2 cells, a human HSC line, stimulated with transforming growth factor-β1 (TGF-β1), a major regulator of HSC fibrosis, with or without irisin. Mitochondrial function was assessed using mitochondrial fission markers, transmission electron microscopy, mitochondrial membrane potential, and adenosine triphosphate (ATP) production. In vivo, liver fibrosis was induced in mice via BDL, followed by daily intraperitoneal injections of irisin (100 μg/kg/day) for 10 days.
Results
In vitro, irisin mitigated HSC activation and reduced reactive oxygen species associated with the TGF-β1/Smad signaling pathway. Irisin restored TGF-β1-induced increases in fission markers (Fis1, p-DRP1) and reversed the decreased expression of TFAM and SIRT3. Additionally, irisin restored mitochondrial membrane potential and ATP production lowered by TGF-β1 treatment. In vivo, irisin ameliorated the elevated liver-to-body weight ratio induced by BDL and alleviated liver fibrosis, as evidenced by Masson’s trichrome staining. Irisin also improved mitochondrial dysfunction induced by BDL surgery.
Conclusion
Irisin effectively attenuated HSC activation, ameliorated liver fibrosis in BDL mice, and improved associated mitochondrial dysfunction. These findings highlight the therapeutic potential of irisin for the treatment of liver fibrosis.
Close layer
Review Article
Adrenal gland
The Fascinating Interplay between Growth Hormone, Insulin-Like Growth Factor-1, and Insulin
Eline C. Nijenhuis-Noort, Kirsten A. Berk, Sebastian J. C. M. M. Neggers, Aart J. van der Lely
Endocrinol Metab. 2024;39(1):83-89.   Published online January 9, 2024
DOI: https://doi.org/10.3803/EnM.2024.101
  • 44,662 View
  • 729 Download
  • 6 Web of Science
  • 7 Crossref
AbstractAbstract PDFPubReader   ePub   
This review intends to provide the reader with a practical overview of several (patho)physiological conditions in which knowledge of the interplay between growth hormone (GH), insulin-like growth factor-1 (IGF-1), and insulin is important. This might help treating physicians in making the right decisions on how to intervene and improve metabolism for the benefit of patients, and to understand why and how metabolism responds in their specific cases. We will specifically address the interplay between GH, IGF-1, and insulin in type 1 and 2 diabetes mellitus, liver cirrhosis, and acromegaly as examples in which this knowledge is truly necessary.

Citations

Citations to this article as recorded by  
  • Insulin-Like Growth Factor Signaling in Alzheimer’s Disease: Pathophysiology and Therapeutic Strategies
    Jie Miao, Yanli Zhang, Chen Su, Qiandan Zheng, Junhong Guo
    Molecular Neurobiology.2025; 62(3): 3195.     CrossRef
  • Signaling pathways and targeted therapies in Ewing sarcoma
    Ke Jia, Li Cao, Yihan Yu, Doudou Jing, Wei Wu, Brian Andrew Van Tine, Zengwu Shao
    Pharmacology & Therapeutics.2025; 266: 108765.     CrossRef
  • IGF-1 and IGF-2 as Molecules Linked to Causes and Consequences of Obesity from Fetal Life to Adulthood: A Systematic Review
    Justyna Szydlowska-Gladysz, Adrianna Edyta Gorecka, Julia Stepien, Izabela Rysz, Iwona Ben-Skowronek
    International Journal of Molecular Sciences.2024; 25(7): 3966.     CrossRef
  • Insulin resistance reduction, intermittent fasting, and human growth hormone: secondary analysis of a randomized trial
    Benjamin D. Horne, Jeffrey L. Anderson, Heidi T. May, Tami L. Bair, Viet T. Le, Leslie Iverson, Kirk U. Knowlton, Joseph B. Muhlestein
    npj Metabolic Health and Disease.2024;[Epub]     CrossRef
  • GHRH in diabetes and metabolism
    Charlotte Steenblock, Stefan R. Bornstein
    Reviews in Endocrine and Metabolic Disorders.2024;[Epub]     CrossRef
  • Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin
    Kevin C. J. Yuen, Rikke Hjortebjerg, Ashok Ainkaran Ganeshalingam, David R. Clemmons, Jan Frystyk
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Expanding the Clinical and Mutational Spectrum of Biallelic POC1A Variants: Characterization of Four Patients and a Comprehensive Review of POC1A‐Related Phenotypes
    Umut Altunoglu, Gozde Tutku Turgut, Esin Karakılıç Özturan, Tuğba Kalaycı, Mert Kaya, Güven Toksoy, Firdevs Baş, Hülya Kayserili, Feyza Darendeliler
    Clinical Genetics.2024;[Epub]     CrossRef
Close layer
Original Article
Diabetes, obesity and metabolism
Phloretin Ameliorates Succinate-Induced Liver Fibrosis by Regulating Hepatic Stellate Cells
Cong Thuc Le, Giang Nguyen, So Young Park, Hanh Nguyen Dong, Yun Kyung Cho, Jae-Ho Lee, Seung-Soon Im, Dae-Hee Choi, Eun-Hee Cho
Endocrinol Metab. 2023;38(4):395-405.   Published online August 3, 2023
DOI: https://doi.org/10.3803/EnM.2023.1661
  • 3,149 View
  • 122 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Hepatic stellate cells (HSCs) are the major cells which play a pivotal role in liver fibrosis. During injury, extracellular stimulators can induce HSCs transdifferentiated into active form. Phloretin showed its ability to protect the liver from injury, so in this research we would like to investigate the effect of phloretin on succinate-induced HSCs activation in vitro and liver fibrosis in vivo study.
Methods
In in vitro, succinate was used to induce HSCs activation, and then the effect of phloretin on activated HSCs was examined. In in vivo, succinate was used to generated liver fibrosis in mouse and phloretin co-treated to check its protection on the liver.
Results
Phloretin can reduce the increase of fibrogenic markers and inhibits the proliferation, migration, and contraction caused by succinate in in vitro experiments. Moreover, an upregulation of proteins associated with aerobic glycolysis occurred during the activation of HSCs, which was attenuated by phloretin treatment. In in vivo experiments, intraperitoneal injection of phloretin decreased expression of fibrotic and glycolytic markers in the livers of mice with sodium succinate diet-induced liver fibrosis. These results suggest that aerobic glycolysis plays critical role in activation of HSCs and succinate can induce liver fibrosis in mice, whereas phloretin has therapeutic potential for treating hepatic fibrosis.
Conclusion
Intraperitoneal injection of phloretin attenuated succinate-induced hepatic fibrosis and alleviates the succinate-induced HSCs activation.

Citations

Citations to this article as recorded by  
  • The potential of flavonoids in hepatic fibrosis: A comprehensive review
    Zhu Wenbo, Han Jianwei, Liu Hua, Tang Lei, Chen Guijuan, Tian Mengfei
    Phytomedicine.2024; 133: 155932.     CrossRef
  • Advancements in Plant-Based Therapeutics for Hepatic Fibrosis: Molecular Mechanisms and Nanoparticulate Drug Delivery Systems
    Alina Ciceu, Ferenc Fenyvesi, Anca Hermenean, Simona Ardelean, Simona Dumitra, Monica Puticiu
    International Journal of Molecular Sciences.2024; 25(17): 9346.     CrossRef
Close layer
Brief Report
Diabetes, obesity and metabolism
Performance of Simple Fibrosis Score in Non-Alcoholic Fatty Liver Disease with and without Type 2 Diabetes
Seung Min Chung, Min Kyu Kang, Jun Sung Moon, Jung Gil Park
Endocrinol Metab. 2023;38(2):277-281.   Published online March 13, 2023
DOI: https://doi.org/10.3803/EnM.2022.1635
  • 3,456 View
  • 119 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
This cross-sectional study enrolled 267 patients with metabolic risk factors and established non-alcoholic fatty liver disease in the prospective cohort. The performance of fibrosis-4 (FIB-4) score (≥1.3) to diagnose advanced fibrosis using transient elastography (liver stiffness measurement [LSM] ≥8 kPa) was analyzed. Comparing patients with type 2 diabetes (T2D, n=87) and without (n=180), not FIB-4, but LSM was significantly higher in T2D (P=0.026). The prevalence of advanced fibrosis was 17.2% in T2D and 12.8% in non-T2D. FIB-4 exhibited higher proportion of false negatives in T2D patients (10.9%) than those without (5.2%). The diagnostic performance of FIB-4 was suboptimal in T2D (area under curve [AUC], 0.653; 95% confidence interval [CI], 0.462 to 0.844) compared to that in non-T2D (AUC, 0.826; 95% CI, 0.724 to 0.927). In conclusion, patients with T2D might be beneficial to conduct transient elastography without screening to avoid missing advanced fibrosis.

Citations

Citations to this article as recorded by  
  • The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease
    Rong Ren, Yanxia Pei, Lufei Kong, Yixin Shi
    Journal of Diabetes and its Complications.2025; 39(2): 108932.     CrossRef
  • Multiple Definitions of Fatty Liver Disease: Which One Most Accurately Predicts Diabetes?
    Eun-Jung Rhee
    Endocrinology and Metabolism.2024; 39(2): 397.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease
    Xiaolong Qi, Jie Li, Cyrielle Caussy, Gao-Jun Teng, Rohit Loomba
    Hepatology.2024;[Epub]     CrossRef
  • Prevalence of High and Moderate Risk of Liver Fibrosis Among Patients With Diabetes at a Noncommunicable Diseases (NCD) Clinic in a Primary Healthcare Center in Northern India
    Anubhav Mondal, Aninda Debnath, Ghurumourthy Dhandapani, Abhishek Sharma, Shveta Lukhmana, Geeta Yadav
    Cureus.2023;[Epub]     CrossRef
Close layer
Original Articles
Diabetes, Obesity and Metabolism
The Effects of Irisin on the Interaction between Hepatic Stellate Cell and Macrophage in Liver Fibrosis
Dinh Vinh Do, So Young Park, Giang Thi Nguyen, Dae Hee Choi, Eun-Hee Cho
Endocrinol Metab. 2022;37(4):620-629.   Published online July 22, 2022
DOI: https://doi.org/10.3803/EnM.2022.1412
  • 6,715 View
  • 222 Download
  • 7 Web of Science
  • 6 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Hepatic stellate cells (HSCs) are the central players interacting with multiple cell types in liver fibrosis. The crosstalk between HSCs and macrophages has recently become clearer. Irisin, an exercise-responsive myokine, was known to have a potentially protective role in liver and renal fibrosis, especially in connection with stellate cells. This study investigated the effects of irisin on the interaction between HSCs and macrophages.
Methods
Tamm-Horsfall protein-1 (THP-1) human monocytes were differentiated into macrophages, polarized into the inflammatory M1 phenotype with lipopolysaccharide. Lieming Xu-2 (LX-2) cells, human HSCs, were treated with conditioned media (CM) from M1 macrophages, with or without recombinant irisin. HSCs responses to CM from M1 macrophages were evaluated regarding activation, proliferation, wound healing, trans-well migration, contractility, and related signaling pathway.
Results
CM from M1 macrophages significantly promoted HSC proliferation, wound healing, transwell migration, and contractility, but not activation of HSCs. Irisin co-treatment attenuated these responses of HSCs to CM. However, CM and irisin treatment did not induce any changes in HSC activation. Further, irisin co-treatment alleviated CM-induced increase of phopho-protein kinase B (pAKT), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of metalloproteinases-1 (TIMP-1).
Conclusion
These findings suggested that irisin may play a protective role in the pathogenesis of liver fibrosis, especially when working in the crosstalk between HSCs and macrophages.

Citations

Citations to this article as recorded by  
  • Irisin and Metastatic Melanoma: Selective Anti-Invasiveness Activity in BRAF Wild-Type Cells
    Simona Serratì, Roberta Zerlotin, Michele Manganelli, Roberta Di Fonte, Manuela Dicarlo, Angela Oranger, Graziana Colaianni, Letizia Porcelli, Amalia Azzariti, Stefania Guida, Maria Grano, Silvia Concetta Colucci, Gabriella Guida
    International Journal of Molecular Sciences.2025; 26(2): 652.     CrossRef
  • The potential of flavonoids in hepatic fibrosis: A comprehensive review
    Zhu Wenbo, Han Jianwei, Liu Hua, Tang Lei, Chen Guijuan, Tian Mengfei
    Phytomedicine.2024; 133: 155932.     CrossRef
  • Irisin Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis in Bile Duct Ligation Mice Model and Improves Mitochondrial Dysfunction
    Thuy Linh Lai, So Young Park, Giang Nguyen, Phuc Thi Minh Pham, Seon Mee Kang, Jeana Hong, Jae-Ho Lee, Seung-Soon Im, Dae-Hee Choi, Eun-Hee Cho
    Endocrinology and Metabolism.2024; 39(6): 908.     CrossRef
  • Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis
    Liang Shan, Fengling Wang, Dandan Zhai, Xiangyun Meng, Jianjun Liu, Xiongwen Lv
    Biomedicine & Pharmacotherapy.2023; 161: 114472.     CrossRef
  • Potential role of irisin in digestive system diseases
    Yueming Zhang, Linxian Zhao, Huan Gao, Jinghui Zhai, Yanqing Song
    Biomedicine & Pharmacotherapy.2023; 166: 115347.     CrossRef
  • The effect of sarcopenia and serum myokines on prognosis and survival in cirrhotic patients: a multicenter cross-sectional study
    Salih Boga, Abdullah Emre Yildirim, Enver Ucbilek, Ali Riza Koksal, Sevil Tokdemir Sisman, Ibrahim Durak, Ilker Sen, Beril Dogu, Erdinc Serin, Ayse Bolat Ucbilek, Makbule Ozge Yildirim, Sukru Mehmet Erturk, Huseyin Alkim, Canan Alkim
    European Journal of Gastroenterology & Hepatology.2022;[Epub]     CrossRef
Close layer
Endocrine Research
Irisin Regulates the Functions of Hepatic Stellate Cells
Hanh Nguyen Dong, So Young Park, Cong Thuc Le, Dae-Hee Choi, Eun-Hee Cho
Endocrinol Metab. 2020;35(3):647-655.   Published online September 22, 2020
DOI: https://doi.org/10.3803/EnM.2020.658
  • 7,780 View
  • 191 Download
  • 14 Web of Science
  • 12 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Hepatic stellate cells (HSCs) are known to play a fundamental role in the progression of liver fibrosis. Once HSCs are activated, they are involved in proliferation, migration, and contractility which are characteristics of liver fibrogenesis. Recent studies have shown that irisin, a myokine secreted during physical exercise, has a protective effect in various metabolic diseases, especially in renal fibrosis. However, whether irisin is involved in HSC activation and other processes associated with liver fibrosis has not yet been investigated. In this study, we reveal the role of irisin in HSC activation as well as in proliferation, migration, and contractile properties of HSCs in vitro.
Methods
LX-2 cells, immortalized human HSCs, were treated with transforming growth factor beta 1 (TGF-β1), a core regulator of HSC fibrosis, with or without irisin, and markers of the aforementioned processes were analyzed. Further, an inflammatory response was stimulated with TGF-β1 and lipopolysaccharide (LPS) in combination with irisin and the expression of cytokines was measured.
Results
Recombinant irisin significantly suppressed the expression of TGF-β1-stimulated fibrosis markers including alpha-smooth muscle actin and collagen type 1 alpha 1 and prevented the TGF-β1-induced proliferation, migration, and contractility of LX-2 cells. Additionally, irisin ameliorated the production of interleukin-6 (IL-6) and IL-1β induced by TGF-β1 and LPS treatments.
Conclusion
These findings suggested that irisin potently improved the progression of hepatic fibrosis by regulating HSC activation, proliferation, migration, contractility, and HSC-mediated production of inflammatory cytokine.

Citations

Citations to this article as recorded by  
  • Amplified response of drug-induced liver fibrosis via immune cell co-culture in a 3D in vitro hepatic fibrosis model
    Hyewon Jung, Mi-lang Kyun, Ji-In Kwon, Jeongha Kim, Ju-Kang Kim, Daeui Park, Yu Bin Lee, Kyoung-Sik Moon
    Biomaterials Science.2024; 12(24): 6351.     CrossRef
  • Serum Irisin, Myostatin, and Myonectin Correlate with Metabolic Health Markers, Liver Disease Progression, and Blood Pressure in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease and Hypertension
    Anna F. Sheptulina, Elvira M. Mamutova, Anastasia Yu. Elkina, Yuriy S. Timofeev, Victoria A. Metelskaya, Anton R. Kiselev, Oxana M. Drapkina
    Metabolites.2024; 14(11): 584.     CrossRef
  • Irisin Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis in Bile Duct Ligation Mice Model and Improves Mitochondrial Dysfunction
    Thuy Linh Lai, So Young Park, Giang Nguyen, Phuc Thi Minh Pham, Seon Mee Kang, Jeana Hong, Jae-Ho Lee, Seung-Soon Im, Dae-Hee Choi, Eun-Hee Cho
    Endocrinology and Metabolism.2024; 39(6): 908.     CrossRef
  • Potential role of irisin in digestive system diseases
    Yueming Zhang, Linxian Zhao, Huan Gao, Jinghui Zhai, Yanqing Song
    Biomedicine & Pharmacotherapy.2023; 166: 115347.     CrossRef
  • Potential role of irisin in lung diseases and advances in research
    Hongna Dong, Xuejiao Lv, Peng Gao, Yuqiu Hao
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Stem bark of Fraxinus rhynchophylla ameliorates the severity of pancreatic fibrosis by regulating the TGF-β/Smad signaling pathway
    Ji-Won Choi, Joon Yeon Shin, Ziqi Zhou, Dong-Uk Kim, Bitna Kweon, Hyuncheol Oh, Youn-Chul Kim, Ho-Joon Song, Gi-Sang Bae, Sung-Joo Park
    Journal of Investigative Medicine.2022; 70(5): 1285.     CrossRef
  • Circadian rhythms and cancers: the intrinsic links and therapeutic potentials
    Li Zhou, Zhe Zhang, Edouard Nice, Canhua Huang, Wei Zhang, Yong Tang
    Journal of Hematology & Oncology.2022;[Epub]     CrossRef
  • Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-κB/NLRP3 signaling pathway
    Yan-fang Deng, Qian-qian Xu, Tian-qi Chen, Jia-xiong Ming, Ya-fen Wang, Li-na Mao, Jia-jun Zhou, Wei-guang Sun, Qun Zhou, Hong Ren, Yong-hui Zhang
    Phytomedicine.2022; 104: 154241.     CrossRef
  • The potential role of FNDC5/irisin in various liver diseases: awakening the sleeping beauties
    Xiaoyu Wang, Lihong Mao, Chaoqun Li, Yangyang Hui, Zihan Yu, Mingyu Sun, Yifan Li, Gaoyue Guo, Wanting Yang, Binxin Cui, Xiaofei Fan, Chao Sun
    Expert Reviews in Molecular Medicine.2022;[Epub]     CrossRef
  • The Effects of Irisin on the Interaction between Hepatic Stellate Cell and Macrophage in Liver Fibrosis
    Dinh Vinh Do, So Young Park, Giang Thi Nguyen, Dae Hee Choi, Eun-Hee Cho
    Endocrinology and Metabolism.2022; 37(4): 620.     CrossRef
  • Hepatic Steatosis Contributes to the Development of Muscle Atrophy via Inter-Organ Crosstalk
    Kenneth Pasmans, Michiel E. Adriaens, Peter Olinga, Ramon Langen, Sander S. Rensen, Frank G. Schaap, Steven W. M. Olde Damink, Florian Caiment, Luc J. C. van Loon, Ellen E. Blaak, Ruth C. R. Meex
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)
    David Carneros, Guillermo López-Lluch, Matilde Bustos
    Nutrients.2020; 12(11): 3472.     CrossRef
Close layer
Clinical Study
Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis
Chan-Hee Jung, Eun-Jung Rhee, Hyemi Kwon, Yoosoo Chang, Seungho Ryu, Won-Young Lee
Endocrinol Metab. 2020;35(1):165-176.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.165
  • 8,134 View
  • 152 Download
  • 34 Web of Science
  • 38 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

We evaluated the association of visceral-to-subcutaneous fat ratio (VSR) with nonalcoholic fatty liver disease (NAFLD) and advanced fibrosis degree based on noninvasive serum fibrosis markers in the general population with NAFLD.

Methods

This is a cross-sectional study, in 7,465 Korean adults who underwent health screening examinations. NAFLD was defined as fatty liver detected on ultrasonography, and visceral and subcutaneous abdominal fat was measured using computed tomography. We predicted fibrosis based on the fibrosis-4 (FIB-4) score and aspartate aminotransferase-to-platelet ratio index (APRI) and categorized the risk for advanced fibrosis as low, indeterminate, or high.

Results

The multivariable-adjusted prevalence ratios for indeterminate to high risk of advanced fibrosis based on FIB-4, determined by comparing the second, third, and fourth quartiles with the first quartile of VSR, were 3.38 (95% confidence interval [CI], 0.64 to 17.97), 9.41 (95% CI, 1.97 to 45.01), and 19.34 (95% CI, 4.06 to 92.18), respectively. The multivariable-adjusted prevalence ratios for intermediate to high degree of fibrosis according to APRI also increased across VSR quartiles (5.04 [95% CI, 2.65 to 9.59], 7.51 [95% CI, 3.91 to 14.42], and 19.55 [95% CI, 9.97 to 38.34], respectively). High VSR was more strongly associated with the prevalence of NAFLD in nonobese subjects than in obese subjects, and the associations between VSR and intermediate to high probability of advanced fibrosis in NAFLD were stronger in obese subjects than in nonobese subjects.

Conclusion

High VSR values predicted increased NAFLD risk and advanced fibrosis risk with NAFLD, and the predictive value of VSR for indeterminate to high risk of advanced fibrosis was higher in obese subjects than in nonobese subjects.

Citations

Citations to this article as recorded by  
  • The relationship between anthropometric indices and non-alcoholic fatty liver disease in adults: a cross-sectional study
    Mina Radmehr, Reza Homayounfar, Abolghasem Djazayery
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Opportunistic Extraction of Quantitative CT Biomarkers: Turning the Incidental Into Prognostic Information
    Mohammad Nazri Md Shah, Raja Rizal Azman, Wai Yee Chan, Kwan Hoong Ng
    Canadian Association of Radiologists Journal.2024; 75(1): 92.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Association between obesity phenotypes and non-alcoholic fatty liver: a large population- based study
    Farid Najafi, Yahya Pasdar, Mehdi Moradi Nazar, Mitra Darbandi
    BMC Endocrine Disorders.2024;[Epub]     CrossRef
  • Regional fat distribution and hepatic fibrosis and steatosis severity in patients with nonalcoholic fatty liver disease and type 2 diabetes
    Asieh Mansour, Saeed Pourhassan, Hadis Gerami, Mohammad Reza Mohajeri‐Tehrani, Marziye Salahshour, Ali Abbasi, Elham Madreseh, Sayed Mahmoud Sajjadi‐Jazi
    Obesity Science & Practice.2024;[Epub]     CrossRef
  • Visceral to subcutaneous fat area ratio predicts severe abdominal adhesions in definitive surgery for anastomotic fistula after small intestine resection
    Fan Yang, Weiliang Tian, Shikun Luo, Wuhan Li, Guoping Zhao, Risheng Zhao, Tao Tian, Yunzhao Zhao, Zheng Yao, Qian Huang
    Scientific Reports.2024;[Epub]     CrossRef
  • Obesity. Reasons, features and prospects
    E. A. Bondareva, E. A. Troshina
    Obesity and metabolism.2024; 21(2): 174.     CrossRef
  • Differential association of abdominal, liver, and epicardial adiposity with anthropometry, diabetes, and cardiac remodeling in Asians
    Vivian Lee, Yiying Han, Desiree-Faye Toh, Jennifer A. Bryant, Redha Boubertakh, Thu-Thao Le, Calvin W. L. Chin
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Serum immunoglobulin A levels: Diagnostic utility in alcoholic liver disease and association with liver fibrosis in steatotic liver disease
    Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Kazuyoshi Nagata, Kenichi Sawa, Kazutaka Niiya, Kazuhiko Nakao
    Biomedical Reports.2024;[Epub]     CrossRef
  • Serial changes in metabolic dysfunction-associated steatotic liver disease after sleeve gastrectomy and their associations with abdominal adiposity: a prospective cohort study
    Chung-Yi Yang, Jian-Han Chen, Chung-Yen Chen, Cheng-Yi Kao, Shiu-Feng Huang, Wen-Yu Chang, Hung-Pin Tu, Jee-Fu Huang, Ming-Lung Yu, Chi-Ming Tai
    Surgery for Obesity and Related Diseases.2024;[Epub]     CrossRef
  • Helicobacter pylori Infection Is Not Associated with Nonalcoholic Fatty Liver Disease: A Two-Year Cohort Study
    Huabo Zheng, Tangmeng Guo, Xiaofang Zhao, Kun Wang, Shengshuai Shan, Songpu Xie, Yichen Xu, Chengyun Liu, Weilin Lu
    Digestive Diseases.2024; : 1.     CrossRef
  • Association between Knowledge and Practice of Thermally Abused Cooking Oil, Serum Lipid Profile, Body Composition, and Waist Circumference of Hyperlipidemia Patients Running Title: Usage of Reused Cooking Oil on Health Parameters
    Siow Lean Yi, Divya Vanoh
    Malaysian Journal of Medicine and Health Sciences.2024; 20(4): 79.     CrossRef
  • Positive Association Between the Chinese Visceral Adiposity Index and Nonalcoholic Fatty Liver Disease in Lean Adults
    Shuxia Shen, Hangkai Huang, Jinghua Wang, Zexi Tang, Chao Shen, Chengfu Xu
    Digestive Diseases and Sciences.2023; 68(2): 656.     CrossRef
  • Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis
    Wolhwa Song, Sung Hwan Yoo, Jinsun Jang, Su Jung Baik, Byoung Kwon Lee, Hyun Woong Lee, Jong Suk Park
    Gut and Liver.2023; 17(1): 130.     CrossRef
  • Using hyperhomocysteinemia and body composition to predict the risk of non-alcoholic fatty liver disease in healthcare workers
    Xiaoyan Hao, Honghai He, Liyuan Tao, Peng Wang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Visceral and subcutaneous fat, muscle mass, and liver volume as noninvasive predictors of the progress of non-alcoholic fatty liver disease
    Omar M. Mahmoud, Gehad Abd Elaziz Mahmoud, Haisam Atta, Wael A. Abbas, Hanan M. Ahmed, Mohamed A. A. Abozaid
    Egyptian Journal of Radiology and Nuclear Medicine.2023;[Epub]     CrossRef
  • Relationship between metabolic associated fatty liver disease and body fat ratio, visceral fat area, and resting metabolic rate estimated by bioelectrical impedance analysis
    Deng-Hua He, Yong-Zhan Zhang, Liang Xu, Jia-Jia Pei, Ying Zhang, Zhong-Fang Yan
    World Chinese Journal of Digestology.2023; 31(2): 56.     CrossRef
  • Poor glycaemic control and ectopic fat deposition mediates the increased risk of non-alcoholic steatohepatitis in high-risk populations with type 2 diabetes: Insights from Bayesian-network modelling
    T. Waddell, A. Namburete, P. Duckworth, A. Fichera, A. Telford, H. Thomaides-Brears, D. J. Cuthbertson, M. Brady
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
  • Subcutaneous Fat Obesity in a High Body Mass Index Donor Is Not a Contraindication to Living Donor Hepatectomy
    Hirak Pahari, Amey Sonavane, Amruth Raj, Anup Kumar Agrawal, Ambreen Sawant, Deepak Kumar Gupta, Amit Gharat, Vikram Raut, Sorabh Kapoor
    Case Reports in Hepatology.2023; 2023: 1.     CrossRef
  • Comparison of cardiometabolic risk factors between obese and non-obese patients with nonalcoholic fatty liver disease
    Zahra Yari, Danial Fotros, Azita Hekmatdoost
    Scientific Reports.2023;[Epub]     CrossRef
  • Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
    Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
    Clinical and Molecular Hepatology.2023; 29(4): 987.     CrossRef
  • Visceral Adipose Tissue Inflammation and Radiographic Visceral-to-Subcutaneous Adipose Tissue Ratio in Patients with Cirrhosis
    Nghiem B. Ha, Soo-Jin Cho, Yara Mohamad, Dorothea Kent, Grace Jun, Randi Wong, Vivek Swarnakar, Shezhang Lin, Jacquelyn J. Maher, Jennifer C. Lai
    Digestive Diseases and Sciences.2022; 67(7): 3436.     CrossRef
  • The Influence of Obesity and Metabolic Health on Vascular Health
    Eun-Jung Rhee
    Endocrinology and Metabolism.2022; 37(1): 1.     CrossRef
  • The effect of combined exercises on the plasma levels of retinol-binding protein 4 and its relationship with insulin resistance and hepatic fat content in postmenopausal women with nonalcoholic fatty liver disease
    Masoumeh NOROUZPOUR, Sayyed M. MARANDI, Mohsen GHANBARZADEH, Abbasali ZARE MAIVAN
    The Journal of Sports Medicine and Physical Fitness.2022;[Epub]     CrossRef
  • The Perirenal Fat Thickness Was Associated with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
    Yuxian Yang, Shuting Li, Yuechao Xu, Jing Ke, Dong Zhao
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1505.     CrossRef
  • Visceral adiposity is an independent risk factor for high intra-operative blood loss during living-donor liver transplantation; could preoperative rehabilitation and nutritional therapy mitigate that risk?
    Mahmoud Macshut, Toshimi Kaido, Siyuan Yao, Yosuke Miyachi, Mohamed Sharshar, Sena Iwamura, Masaaki Hirata, Hisaya Shirai, Naoko Kamo, Shintaro Yagi, Shinji Uemoto
    Clinical Nutrition.2021; 40(3): 956.     CrossRef
  • A review of non‐alcoholic fatty liver disease in non‐obese and lean individuals
    Mitra Ahadi, Kasra Molooghi, Negin Masoudifar, Ali Beheshti Namdar, Hassan Vossoughinia, Mohammadreza Farzanehfar
    Journal of Gastroenterology and Hepatology.2021; 36(6): 1497.     CrossRef
  • Quantification of abdominal fat from computed tomography using deep learning and its association with electronic health records in an academic biobank
    Matthew T MacLean, Qasim Jehangir, Marijana Vujkovic, Yi-An Ko, Harold Litt, Arijitt Borthakur, Hersh Sagreiya, Mark Rosen, David A Mankoff, Mitchell D Schnall, Haochang Shou, Julio Chirinos, Scott M Damrauer, Drew A Torigian, Rotonya Carr, Daniel J Rader
    Journal of the American Medical Informatics Association.2021; 28(6): 1178.     CrossRef
  • Hepatic Steatosis in Patients With Single Ventricle and a Fontan Circulation
    David A. Katz, Daniel Peck, Adam M. Lubert, Mathias Possner, Faizeen Zafar, Andrew T. Trout, Joseph J. Palermo, Nadeem Anwar, Jonathan R. Dillman, Adam W. Powell, Stavra A. Xanthakos, Alexander R. Opotowsky, Gruschen Veldtman, Tarek Alsaied
    Journal of the American Heart Association.2021;[Epub]     CrossRef
  • Superficial vs Deep Subcutaneous Adipose Tissue: Sex-Specific Associations With Hepatic Steatosis and Metabolic Traits
    Tessa Brand, Inge Christina Lamberta van den Munckhof, Marinette van der Graaf, Kiki Schraa, Helena Maria Dekker, Leonardus Antonius Bernardus Joosten, Mihai Gheorghe Netea, Niels Peter Riksen, Jacqueline de Graaf, Joseph Henricus Wilhelmus Rutten
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): e3881.     CrossRef
  • Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study
    Dae-Jeong Koo, Mi Yeon Lee, Inha Jung, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee, Ming-Lung Yu
    PLOS ONE.2021; 16(8): e0255535.     CrossRef
  • Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
    Anne Flint, Grit Andersen, Paul Hockings, Lars Johansson, Anni Morsing, Mads Sundby Palle, Thomas Vogl, Rohit Loomba, Leona Plum‐Mörschel
    Alimentary Pharmacology & Therapeutics.2021; 54(9): 1150.     CrossRef
  • Effects of IL-33 on 3T3-L1 cells and obese mice models induced by a high-fat diet
    Yue Kai, Jingtao Gao, Hu Liu, Yubing Wang, Chenrui Tian, Sheng Guo, Ling He, Min Li, Zhongwei Tian, Xiangfeng Song
    International Immunopharmacology.2021; 101: 108209.     CrossRef
  • Lipid Accumulation Product as an Index for Visceral Obesity and Cardiovascular Risk among a Sample of Obese Egyptian Women
    Nayera E. Hassan, Sahar A. El-Masry, Gamila S. M. El-Saeed, Mohamed S. El Hussieny
    Open Access Macedonian Journal of Medical Sciences.2021; 9(B): 1229.     CrossRef
  • Combined Effects of Dyslipidemia and High Adiposity on the Estimated Glomerular Filtration Rate in a Middle-Aged Chinese Population
    Xichang Wang, Haoyu Wang, Jiashu Li, Xiaotong Gao, Yutong Han, Weiping Teng, Zhongyan Shan, Yaxin Lai
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 4513.     CrossRef
  • Determination of “indeterminate score” measurements in lean nonalcoholic fatty liver disease patients from western Saudi Arabia
    Yasir Mohammed Khayyat
    World Journal of Hepatology.2021; 13(12): 2150.     CrossRef
  • Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population
    Dariusz Narankiewicz, Josefina Ruiz-Nava, Veronica Buonaiuto, María Isabel Ruiz-Moreno, María Dolores López-Carmona, Luis Miguel Pérez-Belmonte, Ricardo Gómez-Huelgas, María Rosa Bernal-López
    International Journal of Environmental Research and Public Health.2020; 17(10): 3518.     CrossRef
Close layer
Case Report
A Case of Multiple Osteoporotic Compression Fractures in Young Man with Budd-Chiari Syndrome.
Sun Hwa Kim, Tae Un Yang, Byeong Kwang Choi, Hye Jin Yoo, Ji A Seo, Kyung Mook Choi, Nan Hee Kim, Sin Gon Kim, Sei Hyun Baik, Dong Seop Choi, Hae Yoon Choi
Endocrinol Metab. 2012;27(4):334-339.   Published online December 20, 2012
DOI: https://doi.org/10.3803/EnM.2012.27.4.334
  • 2,384 View
  • 29 Download
AbstractAbstract PDF
Osteoporosis in young men is extremely rare. In this report, we demonstrate a rare case of multiple vertebral fractures discovered in a young man with Budd-Chiari syndrome without prior history of trauma. A 29-year-old man was diagnosed as Budd-Chiari syndrome 12 years ago and underwent a mesocaval shunt to relieve the hepatic vein obstruction and was on warfarin therapy. He suffered from low back pain and it was not relieved by analgesics. A T-L spine X-ray revealed multiple compression fractures and the z-score at lumbar spine was -3.7 which is below the expected range for that age. The patient was treated with calcium, vitamin D and bisphosphonate, and showed clinical improvement. This case highlights the importance of the investigation for secondary osteoporosis in young adults with an underlying disease that alters bone metabolism.
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP